Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO29564 | Farfarae flos | NA | NA | NA | TCMSP* |
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 52.48 | nM | 16279787 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Inhibition | = | 89.3 | % | 17287126 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Inhibition | = | 91.1 | % | 17287126 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Inhibition | = | 83.8 | % | 17287126 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Inhibition | = | 92.5 | % | 17287126 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 100 | % | 17580845 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 3 | % | 17580845 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 6 | % | 17580845 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 6.1 | nM | 19072235 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Ki | = | 2.2 | nM | 19072235 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Activity | = | 7.4 | % | 18558747 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Activity | = | 3.9 | % | 16643058 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 11.5 | nM | 18640836 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 0.89 | nM | 18590272 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 0.89 | nM | 20148564 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Activity | = | 4.90E-05 | ug/ml | 20148564 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 85 | % | 20148564 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 0 | % | 20148564 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Inhibition | = | 87.9 | % | 20102168 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Inhibition | = | 87.5 | % | 20102168 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Inhibition | = | 81.7 | % | 20102168 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Inhibition | = | 91.1 | % | 20102168 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 11.5 | nM | 20413308 |
NPT306 | Cell Line | PC-3 | Homo sapiens | FC | = | 1.001 | 16680159 | |
NPT210 | Individual Protein | Thyroid stimulating hormone receptor | Homo sapiens | Potency | = | 7943.3 | nM | PubChem BioAssay data set |
NPT213 | Individual Protein | Cytochrome P450 2C19 | Homo sapiens | Potency | = | 7943.3 | nM | PubChem BioAssay data set |
NPT109 | Individual Protein | Cytochrome P450 3A4 | Homo sapiens | Potency | = | 5011.9 | nM | PubChem BioAssay data set |
NPT400 | Cell Line | MDA-MB-435 | Homo sapiens | GI50 | = | 67 | nM | 20950898 |
NPT458 | Cell Line | IGROV-1 | Homo sapiens | GI50 | = | 95 | nM | 20950898 |
NPT82 | Cell Line | MDA-MB-231 | Homo sapiens | GI50 | = | 150 | nM | 20950898 |
NPT396 | Cell Line | T47D | Homo sapiens | GI50 | = | 440 | nM | 20950898 |
NPT83 | Cell Line | MCF7 | Homo sapiens | GI50 | = | 700 | nM | 20950898 |
NPT456 | Cell Line | OVCAR-4 | Homo sapiens | GI50 | = | 880 | nM | 20950898 |
NPT457 | Cell Line | BT-549 | Homo sapiens | GI50 | = | 890 | nM | 20950898 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Activity | = | 1 | % | 20950898 |
NPT146 | Cell Line | SK-OV-3 | Homo sapiens | GI50 | = | 1090 | nM | 20950898 |
NPT378 | Cell Line | NCI/ADR-RES | Homo sapiens | GI50 | = | 1160 | nM | 20950898 |
NPT367 | Cell Line | MDA-N | Homo sapiens | GI50 | = | 1610 | nM | 20950898 |
NPT382 | Cell Line | OVCAR-5 | Homo sapiens | GI50 | = | 1620 | nM | 20950898 |
NPT2 | Others | Unspecified | GI50 | = | 2170 | nM | 20950898 | |
NPT381 | Cell Line | OVCAR-8 | Homo sapiens | GI50 | = | 4500 | nM | 20950898 |
NPT377 | Cell Line | OVCAR-3 | Homo sapiens | GI50 | = | 5870 | nM | 20950898 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Activity | = | 21.65 | % | 20950898 |
NPT32 | Organism | Mus musculus | Mus musculus | LD50 | = | 252.61 | mg/kg | 20950898 |
NPT533 | Protein-Protein Interaction | Runt-related transcription factor 1/Core-binding factor subunit beta | Homo sapiens | Potency | 11220.2 | nM | PubChem BioAssay data set | |
NPT109 | Individual Protein | Cytochrome P450 3A4 | Homo sapiens | AC50 | = | 5011.87 | nM | PubChem BioAssay data set |
NPT213 | Individual Protein | Cytochrome P450 2C19 | Homo sapiens | AC50 | = | 7943.28 | nM | PubChem BioAssay data set |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 18 | nM | 21497425 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 4.2 | nM | 21604760 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 8 | nM | 21703734 |
NPT3158 | Cell Line | NCI-H295R | Homo sapiens | GI | = | 10 | % | 21703734 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Ratio IC50 | = | 2 | 21703734 | |
NPT198 | Individual Protein | Vitamin D receptor | Homo sapiens | Potency | 14125.4 | nM | PubChem BioAssay data set | |
NPT444 | Individual Protein | Ubiquitin carboxyl-terminal hydrolase 1 | Homo sapiens | Potency | 39810.7 | nM | PubChem BioAssay data set | |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 1 | nM | 22335894 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 2 | nM | 22386564 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Ki | = | 0.02 | nM | 22386564 |
NPT533 | Protein-Protein Interaction | Runt-related transcription factor 1/Core-binding factor subunit beta | Homo sapiens | Potency | 15087.5 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | 41762.9 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | EC50 | = | 0.004 | nM | 22951074 | |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 9.9 | nM | 22951074 |
NPT2 | Others | Unspecified | Activity | = | 98 | % | 10.1007/s00044-012-0133-8 | |
NPT2 | Others | Unspecified | Activity | = | 80 | % | 10.1007/s00044-012-0133-8 | |
NPT2 | Others | Unspecified | Activity | = | 60 | % | 10.1007/s00044-012-0133-8 | |
NPT2 | Others | Unspecified | Activity | = | 32 | % | 10.1007/s00044-012-0133-8 | |
NPT2 | Others | Unspecified | Activity | = | 22 | % | 10.1007/s00044-012-0133-8 | |
NPT3159 | Individual Protein | Cytochrome P450 17A1 | Homo sapiens | Inhibition | = | 7 | % | 23281812 |
NPT2 | Others | Unspecified | Ratio IC50 | = | 1.8 | 23281812 | ||
NPT3160 | Individual Protein | Cytochrome P450 11B2 | Homo sapiens | IC50 | = | 1420 | nM | 23281812 |
NPT3161 | Individual Protein | Cytochrome P450 11B1 | Homo sapiens | IC50 | = | 2620 | nM | 23281812 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 36 | nM | 23281812 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 16.53 | nM | 23403081 |
NPT3158 | Cell Line | NCI-H295R | Homo sapiens | GI50 | > | 100000 | nM | 24025069 |
NPT377 | Cell Line | OVCAR-3 | Homo sapiens | GI50 | > | 100000 | nM | 24025069 |
NPT458 | Cell Line | IGROV-1 | Homo sapiens | GI50 | > | 100000 | nM | 24025069 |
NPT83 | Cell Line | MCF7 | Homo sapiens | GI50 | > | 100000 | nM | 24025069 |
NPT139 | Cell Line | HT-29 | Homo sapiens | GI50 | > | 100000 | nM | 24025069 |
NPT165 | Cell Line | HeLa | Homo sapiens | GI50 | > | 100000 | nM | 24025069 |
NPT15 | Cell Line | Jurkat | Homo sapiens | GI50 | > | 100000 | nM | 24025069 |
NPT2 | Others | Unspecified | GI50 | > | 100000 | nM | 24025069 | |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Activity | = | 32 | % | 24025069 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 3.4 | nM | 24025069 |
NPT83 | Cell Line | MCF7 | Homo sapiens | IC50 | = | 20 | nM | 24345481 |
NPT83 | Cell Line | MCF7 | Homo sapiens | IC50 | = | 7 | nM | 24345481 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 2.8 | nM | 24345481 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 1.1 | nM | 10.1039/C3MD00166K |
NPT2 | Others | Unspecified | Potency | 9432.9 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 10490.4 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 3.3 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 1058.4 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 6678 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 7426.6 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 6441.8 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 51008.7 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 1.1 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 2266.4 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 9.1 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 14.3 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 25788.8 | nM | PubChem BioAssay data set | ||
NPT3161 | Individual Protein | Cytochrome P450 11B1 | Homo sapiens | Inhibition | = | 16.4 | % | 10.1039/C2MD20072D |
NPT3160 | Individual Protein | Cytochrome P450 11B2 | Homo sapiens | Inhibition | = | 25.6 | % | 10.1039/C2MD20072D |
NPT3159 | Individual Protein | Cytochrome P450 17A1 | Homo sapiens | Inhibition | = | 6.8 | % | 10.1039/C2MD20072D |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | Inhibition | = | 99 | % | 10.1039/C2MD20072D |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 36.2 | nM | 10.1039/C2MD20072D |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 5.3 | nM | 25751283 |
NPT2 | Others | Unspecified | AC50 | 450 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | AC50 | 354.8 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 29565.9 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 93.5 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 9349.5 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 20931 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | AC50 | 281.8 | nM | PubChem BioAssay data set | ||
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 3.3 | nM | 25934226 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 0.89 | nM | 25992880 |
NPT441 | Individual Protein | Cytochrome P450 19A1 | Homo sapiens | IC50 | = | 4 | nM | 27161804 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC52764 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.6226 | Remote Similarity | NPC469975 |
0.6142 | Remote Similarity | NPC108339 |
0.6063 | Remote Similarity | NPC322040 |
0.6015 | Remote Similarity | NPC469974 |
0.5969 | Remote Similarity | NPC471319 |
0.5969 | Remote Similarity | NPC471320 |
0.5906 | Remote Similarity | NPC470926 |
0.5839 | Remote Similarity | NPC164802 |
0.578 | Remote Similarity | NPC317054 |
0.5772 | Remote Similarity | NPC119677 |
0.5769 | Remote Similarity | NPC329430 |
0.5738 | Remote Similarity | NPC231986 |
0.5726 | Remote Similarity | NPC169016 |
0.5692 | Remote Similarity | NPC469330 |
0.5669 | Remote Similarity | NPC150259 |
0.5664 | Remote Similarity | NPC288232 |
0.5644 | Remote Similarity | NPC114209 |
0.563 | Remote Similarity | NPC98976 |
0.563 | Remote Similarity | NPC239854 |
0.562 | Remote Similarity | NPC474695 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC52764 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
1.0 | High Similarity | NPD2294 | Approved |
0.871 | High Similarity | NPD2477 | Approved |
0.8417 | Intermediate Similarity | NPD2776 | Clinical (unspecified phase) |
0.808 | Intermediate Similarity | NPD2537 | Clinical (unspecified phase) |
0.7569 | Intermediate Similarity | NPD1863 | Clinical (unspecified phase) |
0.7075 | Intermediate Similarity | NPD4864 | Approved |
0.6974 | Remote Similarity | NPD1257 | Approved |
0.6948 | Remote Similarity | NPD5971 | Clinical (unspecified phase) |
0.6933 | Remote Similarity | NPD2992 | Approved |
0.6824 | Remote Similarity | NPD960 | Approved |
0.6732 | Remote Similarity | NPD2764 | Clinical (unspecified phase) |
0.6731 | Remote Similarity | NPD939 | Clinical (unspecified phase) |
0.6689 | Remote Similarity | NPD4849 | Approved |
0.6623 | Remote Similarity | NPD7307 | Approved |
0.6623 | Remote Similarity | NPD7306 | Approved |
0.6601 | Remote Similarity | NPD974 | Approved |
0.6593 | Remote Similarity | NPD403 | Clinical (unspecified phase) |
0.6536 | Remote Similarity | NPD3629 | Approved |
0.6536 | Remote Similarity | NPD3630 | Approved |
0.6529 | Remote Similarity | NPD6730 | Discontinued |
0.6488 | Remote Similarity | NPD3235 | Clinical (unspecified phase) |
0.6471 | Remote Similarity | NPD1887 | Clinical (unspecified phase) |
0.6444 | Remote Similarity | NPD6562 | Approved |
0.6444 | Remote Similarity | NPD6561 | Approved |
0.6416 | Remote Similarity | NPD5815 | Clinical (unspecified phase) |
0.6393 | Remote Similarity | NPD9 | Approved |
0.6393 | Remote Similarity | NPD297 | Approved |
0.6392 | Remote Similarity | NPD4853 | Approved |
0.6374 | Remote Similarity | NPD4964 | Clinical (unspecified phase) |
0.6306 | Remote Similarity | NPD1011 | Discontinued |
0.6291 | Remote Similarity | NPD544 | Clinical (unspecified phase) |
0.6279 | Remote Similarity | NPD1860 | Approved |
0.6271 | Remote Similarity | NPD2362 | Approved |
0.6258 | Remote Similarity | NPD1988 | Phase 1 |
0.625 | Remote Similarity | NPD2063 | Clinical (unspecified phase) |
0.6235 | Remote Similarity | NPD1893 | Phase 2 |
0.6235 | Remote Similarity | NPD1167 | Phase 3 |
0.6235 | Remote Similarity | NPD1892 | Phase 2 |
0.6226 | Remote Similarity | NPD3612 | Phase 2 |
0.622 | Remote Similarity | NPD2738 | Approved |
0.6218 | Remote Similarity | NPD1690 | Clinical (unspecified phase) |
0.6211 | Remote Similarity | NPD4595 | Approved |
0.6207 | Remote Similarity | NPD5642 | Approved |
0.6203 | Remote Similarity | NPD5972 | Discontinued |
0.6201 | Remote Similarity | NPD2960 | Clinical (unspecified phase) |
0.6176 | Remote Similarity | NPD2293 | Phase 2 |
0.6168 | Remote Similarity | NPD3232 | Clinical (unspecified phase) |
0.6163 | Remote Similarity | NPD1707 | Approved |
0.6163 | Remote Similarity | NPD1708 | Approved |
0.6139 | Remote Similarity | NPD1943 | Approved |
0.6139 | Remote Similarity | NPD1942 | Approved |
0.6116 | Remote Similarity | NPD5178 | Approved |
0.6116 | Remote Similarity | NPD2539 | Approved |
0.6116 | Remote Similarity | NPD2538 | Approved |
0.6101 | Remote Similarity | NPD4371 | Clinical (unspecified phase) |
0.6095 | Remote Similarity | NPD5324 | Clinical (unspecified phase) |
0.6094 | Remote Similarity | NPD5964 | Phase 2 |
0.6094 | Remote Similarity | NPD5963 | Phase 2 |
0.609 | Remote Similarity | NPD5440 | Discontinued |
0.6076 | Remote Similarity | NPD962 | Phase 3 |
0.6076 | Remote Similarity | NPD6305 | Clinical (unspecified phase) |
0.6069 | Remote Similarity | NPD6731 | Clinical (unspecified phase) |
0.6069 | Remote Similarity | NPD1637 | Clinical (unspecified phase) |
0.6063 | Remote Similarity | NPD8 | Approved |
0.6063 | Remote Similarity | NPD243 | Approved |
0.6063 | Remote Similarity | NPD6548 | Approved |
0.6063 | Remote Similarity | NPD6549 | Approved |
0.6057 | Remote Similarity | NPD2724 | Phase 1 |
0.6047 | Remote Similarity | NPD3409 | Phase 1 |
0.6044 | Remote Similarity | NPD4470 | Phase 2 |
0.6043 | Remote Similarity | NPD7062 | Discontinued |
0.6032 | Remote Similarity | NPD3000 | Approved |
0.6032 | Remote Similarity | NPD2997 | Approved |
0.6032 | Remote Similarity | NPD2998 | Approved |
0.6016 | Remote Similarity | NPD305 | Approved |
0.6016 | Remote Similarity | NPD304 | Approved |
0.6015 | Remote Similarity | NPD488 | Approved |
0.6015 | Remote Similarity | NPD489 | Approved |
0.6 | Remote Similarity | NPD9351 | Phase 3 |
0.6 | Remote Similarity | NPD724 | Approved |
0.6 | Remote Similarity | NPD2445 | Approved |
0.6 | Remote Similarity | NPD9348 | Approved |
0.6 | Remote Similarity | NPD9349 | Approved |
0.6 | Remote Similarity | NPD9350 | Approved |
0.6 | Remote Similarity | NPD2446 | Approved |
0.5978 | Remote Similarity | NPD4892 | Clinical (unspecified phase) |
0.5967 | Remote Similarity | NPD1912 | Approved |
0.5967 | Remote Similarity | NPD4294 | Phase 2 |
0.5957 | Remote Similarity | NPD6660 | Discontinued |
0.5954 | Remote Similarity | NPD1946 | Clinical (unspecified phase) |
0.5952 | Remote Similarity | NPD6794 | Approved |
0.5943 | Remote Similarity | NPD1332 | Clinical (unspecified phase) |
0.5933 | Remote Similarity | NPD4867 | Approved |
0.5933 | Remote Similarity | NPD3841 | Phase 3 |
0.5933 | Remote Similarity | NPD4866 | Approved |
0.592 | Remote Similarity | NPD5675 | Discontinued |
0.592 | Remote Similarity | NPD3310 | Approved |
0.5917 | Remote Similarity | NPD2333 | Discontinued |
0.5915 | Remote Similarity | NPD2927 | Phase 3 |
0.5912 | Remote Similarity | NPD2320 | Discontinued |
0.5903 | Remote Similarity | NPD5961 | Clinical (unspecified phase) |
0.5901 | Remote Similarity | NPD176 | Clinical (unspecified phase) |
0.5896 | Remote Similarity | NPD2315 | Approved |
0.5891 | Remote Similarity | NPD5554 | Approved |
0.5886 | Remote Similarity | NPD1895 | Discontinued |
0.5882 | Remote Similarity | NPD2875 | Clinical (unspecified phase) |
0.5878 | Remote Similarity | NPD6498 | Approved |
0.5878 | Remote Similarity | NPD1950 | Approved |
0.5878 | Remote Similarity | NPD6499 | Approved |
0.5878 | Remote Similarity | NPD1949 | Approved |
0.5873 | Remote Similarity | NPD5656 | Clinical (unspecified phase) |
0.5872 | Remote Similarity | NPD3799 | Suspended |
0.5867 | Remote Similarity | NPD3424 | Clinical (unspecified phase) |
0.5862 | Remote Similarity | NPD3341 | Clinical (unspecified phase) |
0.586 | Remote Similarity | NPD6151 | Phase 2 |
0.5852 | Remote Similarity | NPD5493 | Clinical (unspecified phase) |
0.5847 | Remote Similarity | NPD6278 | Clinical (unspecified phase) |
0.5844 | Remote Similarity | NPD2142 | Approved |
0.5844 | Remote Similarity | NPD2140 | Approved |
0.5844 | Remote Similarity | NPD2141 | Approved |
0.5843 | Remote Similarity | NPD5476 | Clinical (unspecified phase) |
0.5839 | Remote Similarity | NPD477 | Phase 1 |
0.5822 | Remote Similarity | NPD4323 | Clinical (unspecified phase) |
0.5821 | Remote Similarity | NPD154 | Discontinued |
0.5815 | Remote Similarity | NPD3228 | Phase 1 |
0.5814 | Remote Similarity | NPD1958 | Clinical (unspecified phase) |
0.5806 | Remote Similarity | NPD2205 | Approved |
0.5806 | Remote Similarity | NPD2208 | Approved |
0.5802 | Remote Similarity | NPD5598 | Approved |
0.5802 | Remote Similarity | NPD5597 | Approved |
0.5801 | Remote Similarity | NPD2774 | Clinical (unspecified phase) |
0.58 | Remote Similarity | NPD7582 | Discontinued |
0.5799 | Remote Similarity | NPD2786 | Discontinued |
0.5799 | Remote Similarity | NPD1313 | Approved |
0.5795 | Remote Similarity | NPD5806 | Clinical (unspecified phase) |
0.5795 | Remote Similarity | NPD2301 | Approved |
0.5795 | Remote Similarity | NPD4649 | Clinical (unspecified phase) |
0.5793 | Remote Similarity | NPD2340 | Discontinued |
0.5793 | Remote Similarity | NPD3906 | Approved |
0.5789 | Remote Similarity | NPD3475 | Approved |
0.5789 | Remote Similarity | NPD3476 | Approved |
0.5783 | Remote Similarity | NPD5300 | Clinical (unspecified phase) |
0.5767 | Remote Similarity | NPD2465 | Approved |
0.5767 | Remote Similarity | NPD2462 | Phase 3 |
0.5767 | Remote Similarity | NPD2466 | Phase 3 |
0.5763 | Remote Similarity | NPD4441 | Phase 2 |
0.5756 | Remote Similarity | NPD6827 | Clinical (unspecified phase) |
0.5756 | Remote Similarity | NPD6828 | Phase 2 |
0.5754 | Remote Similarity | NPD2793 | Discontinued |
0.5746 | Remote Similarity | NPD2483 | Discontinued |
0.5745 | Remote Similarity | NPD5064 | Approved |
0.5745 | Remote Similarity | NPD6129 | Phase 2 |
0.5745 | Remote Similarity | NPD5063 | Approved |
0.5743 | Remote Similarity | NPD4855 | Phase 1 |
0.5743 | Remote Similarity | NPD4856 | Approved |
0.574 | Remote Similarity | NPD6266 | Approved |
0.5738 | Remote Similarity | NPD3035 | Approved |
0.5736 | Remote Similarity | NPD4408 | Approved |
0.5736 | Remote Similarity | NPD4405 | Approved |
0.5736 | Remote Similarity | NPD4407 | Approved |
0.5725 | Remote Similarity | NPD157 | Clinical (unspecified phase) |
0.5723 | Remote Similarity | NPD2768 | Approved |
0.5723 | Remote Similarity | NPD2767 | Approved |
0.5723 | Remote Similarity | NPD966 | Clinical (unspecified phase) |
0.5714 | Remote Similarity | NPD1288 | Clinical (unspecified phase) |
0.5714 | Remote Similarity | NPD5995 | Clinical (unspecified phase) |
0.5714 | Remote Similarity | NPD6761 | Discontinued |
0.5714 | Remote Similarity | NPD1272 | Clinical (unspecified phase) |
0.5707 | Remote Similarity | NPD5816 | Discontinued |
0.5707 | Remote Similarity | NPD5464 | Approved |
0.5706 | Remote Similarity | NPD3889 | Approved |
0.5706 | Remote Similarity | NPD5492 | Discontinued |
0.5699 | Remote Similarity | NPD3287 | Clinical (unspecified phase) |
0.5697 | Remote Similarity | NPD1917 | Discontinued |
0.5695 | Remote Similarity | NPD1598 | Discontinued |
0.5691 | Remote Similarity | NPD4170 | Approved |
0.5691 | Remote Similarity | NPD4169 | Approved |
0.5691 | Remote Similarity | NPD4701 | Clinical (unspecified phase) |
0.569 | Remote Similarity | NPD7006 | Approved |
0.5685 | Remote Similarity | NPD6892 | Discontinued |
0.5683 | Remote Similarity | NPD2839 | Phase 2 |
0.568 | Remote Similarity | NPD3249 | Discontinued |
0.568 | Remote Similarity | NPD9505 | Clinical (unspecified phase) |
0.5676 | Remote Similarity | NPD3622 | Clinical (unspecified phase) |
0.5676 | Remote Similarity | NPD3623 | Clinical (unspecified phase) |
0.5673 | Remote Similarity | NPD6811 | Approved |
0.5671 | Remote Similarity | NPD1027 | Approved |
0.5671 | Remote Similarity | NPD1030 | Approved |
0.5671 | Remote Similarity | NPD1029 | Clinical (unspecified phase) |
0.5667 | Remote Similarity | NPD3378 | Clinical (unspecified phase) |
0.5667 | Remote Similarity | NPD5838 | Phase 2 |
0.5667 | Remote Similarity | NPD4902 | Discontinued |
0.5665 | Remote Similarity | NPD3347 | Clinical (unspecified phase) |
0.5656 | Remote Similarity | NPD5372 | Approved |
0.5656 | Remote Similarity | NPD5371 | Approved |
0.5652 | Remote Similarity | NPD6265 | Discontinued |
0.565 | Remote Similarity | NPD1873 | Clinical (unspecified phase) |
0.565 | Remote Similarity | NPD5508 | Phase 1 |
0.5647 | Remote Similarity | NPD404 | Discontinued |
0.5645 | Remote Similarity | NPD5462 | Discontinued |
PubChem CID   | 3902 |
ChEMBL   | CHEMBL1444 |
ZINC   |
Molecular Weight:   | 285.10 |
ALogP:   | 0.0322 |
MLogP:   | 2.78 |
XLogP:   | 3.014 |
# Rotatable Bonds:   | 3 |
Polar Surface Area:   | 78.29 |
# H-Bond Aceptor:   | 5 |
# H-Bond Donor:   | 0 |
# Rings:   | 3 |
# Heavy Atoms:   | 22 |